Foghorn Therapeutics/$FHTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Foghorn Therapeutics
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Ticker
$FHTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
112
ISIN
US3441741077
Website
FHTX Metrics
BasicAdvanced
$328M
-
-$1.34
3.13
-
Price and volume
Market cap
$328M
Beta
3.13
52-week high
$9.53
52-week low
$2.94
Average daily volume
145K
Financial strength
Current ratio
3.161
Quick ratio
3.093
Long term debt to equity
-41.747
Total debt to equity
-56.53
Profitability
EBITDA (TTM)
-91.892
Gross margin (TTM)
-285.55%
Net profit margin (TTM)
-342.23%
Operating margin (TTM)
-404.20%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-23.12%
Return on equity (TTM)
101.09%
Valuation
Price to revenue (TTM)
15.011
Price to book
-5.31
Price to tangible book (TTM)
-5.31
Price to free cash flow (TTM)
-3.681
Free cash flow yield (TTM)
-27.17%
Free cash flow per share (TTM)
-159.76%
Growth
Revenue change (TTM)
-30.66%
Earnings per share change (TTM)
-39.24%
3-year revenue growth (CAGR)
68.04%
3-year earnings per share growth (CAGR)
-21.27%
What the Analysts think about FHTX
Analyst ratings (Buy, Hold, Sell) for Foghorn Therapeutics stock.
Bulls say / Bears say
Foghorn Therapeutics has received a 'Strong Buy' rating from B. Riley, indicating strong confidence in the company's future prospects. (marketbeat.com)
The company has a robust pipeline, including proprietary programs like Selective CBP, Selective EP300, and ARID1B, as well as a collaboration with Lilly for developing FHD-909, showcasing a diversified approach to oncology treatments. (benzinga.com)
Analysts have been steadily raising their earnings estimates for Foghorn Therapeutics, with the Zacks Consensus Estimate for the company increasing by 41.5% over the past three months, reflecting optimism about its financial performance. (nasdaq.com)
Foghorn Therapeutics reported a Q4 loss of $0.30 per share, slightly missing the Zacks Consensus Estimate of a loss of $0.29, indicating challenges in meeting earnings expectations. (nasdaq.com)
The company announced the discontinuation of its FHD-286 program for relapsed/refractory acute myeloid leukemia due to insufficient response rates in a Phase 1 trial, which could raise concerns about the efficacy of its pipeline. (benzinga.com)
Jefferies Financial Group reduced its price target for Foghorn Therapeutics from $18.00 to $14.00, reflecting a more cautious outlook on the company's stock performance. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 14 Jul 2025.
FHTX Financial Performance
Revenues and expenses
FHTX Earnings Performance
Company profitability
FHTX News
AllArticlesVideos
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
GlobeNewsWire·2 months ago
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
GlobeNewsWire·2 months ago
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Foghorn Therapeutics stock?
Foghorn Therapeutics (FHTX) has a market cap of $328M as of July 15, 2025.
What is the P/E ratio for Foghorn Therapeutics stock?
The price to earnings (P/E) ratio for Foghorn Therapeutics (FHTX) stock is 0 as of July 15, 2025.
Does Foghorn Therapeutics stock pay dividends?
No, Foghorn Therapeutics (FHTX) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Foghorn Therapeutics dividend payment date?
Foghorn Therapeutics (FHTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Foghorn Therapeutics?
Foghorn Therapeutics (FHTX) has a beta rating of 3.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.